Gold Prices Slip From Two-Month High as Inflation and Fed Outlook Drive Markets 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
US Dollar Slips as Weak Retail Sales Reduce Fed Rate Hike Bets 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Wall Street Hits Record High as Softer Inflation Data Eases Fed Rate Hike Fears 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Asian Currencies Edge Higher as Soft US Inflation Weighs on Dollar 
US Dollar Slips as Softer PPI Data Eases Fed Rate Hike Expectations 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Add as a preferred source on Google
Celltrion Inc., a biopharmaceutical company headquartered in Incheon, South Korea, is merging with its Celltrion Healthcare subsidiary in an effort to strengthen its business synergy or combined effort. The biosimilar producer and its biosimilar marketing unit are set to be consolidated this year.
Seo Jung Jin, Celltrion Group’s chairman, said on Thursday, Aug. 17, that once Celltrion is incorporated with Celltrion Healthcare, the newly-formed entity will also take in Celltrion Pharma. The chairman said this integration will eventually happen later but did not provide an exact time frame. After all the mergings, Celltrion, Celltrion Healthcare, and the company’s chemical pharma producer will work together as one.
According to The Korea Times, Celltrion revealed its plan to acquire Celltrion Healthcare during the company’s recent regulatory filing. The changes will also entail the issuance of new shares of Celltrion to shareholders of Celltrion Healthcare, and the merger ratio is expected to stand at 1:0.4492620.
It was mentioned that the Celltrion chairman holds a 95% stake in Celltrion Holdings which in turn holds a 20.02% stake in Celltrion. The holdings also have a 35.54% stake in Celltrion Healthcare and a 54.96% stake in Celltrion Pharm.
"Celltrion is expected to complete the merger of Celltrion Healthcare by the end of the year, followed by the next merger with Celltrion Pharm in the next six months," Seo Jung Jin shared during an online conference.
The Celltrion Group said it will merge the mentioned companies, but the plan still needs the approval of shareholders. This may be completed on October 23 at the shareholders' meeting. Celltrion and Celltrion Healthcare will eventually be dissolved after the merger.
To date, while the merger is still being processed, The Korea Herald reported that Celltrion is focusing on producing and developing bio-pharmaceutical products while Celltrion Healthcare is working more on selling these products.
Photo by: Celltrion Press Room
